scholarly journals Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics

2011 ◽  
Vol 96 (2) ◽  
pp. E330-E339 ◽  
Author(s):  
Étienne Audet-Walsh ◽  
Johanie Lépine ◽  
Jean Grégoire ◽  
Marie Plante ◽  
Patrick Caron ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Postmenopausal Women ◽  
Clinical Characteristics ◽  
Estrogenic Activity ◽  
Low Grade ◽  
Type I ◽  
Healthy Women ◽  
Increased Risk ◽  
Risk Of Cancer ◽  
Circulating Levels

abstract Background: Endometrial cancer (EC) predominantly occurs after menopause and is strongly related to steroid hormones, particularly estrogens. However, the relationship between these hormones and clinical characteristics remains unaddressed. Experimental Design: We analyzed the circulating levels of 18 steroids including adrenal precursors, androgens, estrogens, and their glucuronide metabolites, using specific and validated methods based on tandem mass spectrometry. Our goals were to compare circulating levels in postmenopausal women with EC (n = 126) with those of healthy postmenopausal women (n = 110) and to investigate how these hormonal levels relate to clinical characteristics. Results: After adjustment for potential confounders, most hormones were significantly elevated in EC patients compared with healthy controls. In women with type I cancer, estrogen levels were up to 3-fold those of healthy women (P < 0.05). These higher levels were associated with an increased risk of cancer, particularly estrogens and their direct precursors, testosterone and androstenedione (odds ratios ranging from 4.4 to 13.3; P ≤ 0.0003). Elevated circulating levels of estrogens and their metabolites were found in cancer cases with type I endometrioid cancer and low-grade and noninvasive tumor, suggesting an association between these hormones and the tumoral estrogenic activity. In addition, levels of estrone-sulfate in EC patients with relapse were 2-fold over levels of EC patients without relapse (P < 0.05), and 4.5-fold over those of healthy women (P < 0.001). Conclusions: Circulating levels of steroids were associated with increased risk of EC. Estrogens may represent novel biomarkers predictive of clinical characteristics, including evidence for an increased risk of relapse.

scholarly journals Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics

Endocrinology ◽  
2011 ◽  
Vol 152 (1) ◽  
pp. 335-335
Author(s):  
Étienne Audet-Walsh ◽  
Johanie Lépine ◽  
Jean Grégoire ◽  
Marie Plante ◽  
Patrick Caron ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Postmenopausal Women ◽  
Clinical Characteristics ◽  
Estrogenic Activity ◽  
Low Grade ◽  
Type I ◽  
Healthy Women ◽  
Increased Risk ◽  
Risk Of Cancer ◽  
Circulating Levels

Background: Endometrial cancer (EC) predominantly occurs after menopause and is strongly related to steroid hormones, particularly estrogens. However, the relationship between these hormones and clinical characteristics remains unaddressed. Experimental Design: We analyzed the circulating levels of 18 steroids including adrenal precursors, androgens, estrogens, and their glucuronide metabolites, using specific and validated methods based on tandem mass spectrometry. Our goals were to compare circulating levels in postmenopausal women with EC (n = 126) with those of healthy postmenopausal women (n = 110) and to investigate how these hormonal levels relate to clinical characteristics. Results: After adjustment for potential confounders, most hormones were significantly elevated in EC patients compared with healthy controls. In women with type I cancer, estrogen levels were up to 3-fold those of healthy women (P < 0.05). These higher levels were associated with an increased risk of cancer, particularly estrogens and their direct precursors, testosterone and androstenedione (odds ratios ranging from 4.4 to 13.3; P ≤ 0.0003). Elevated circulating levels of estrogens and their metabolites were found in cancer cases with type I endometrioid cancer and low-grade and noninvasive tumor, suggesting an association between these hormones and the tumoral estrogenic activity. In addition, levels of estrone sulfate in EC patients with relapse were 2-fold over levels of EC patients without relapse (P < 0.05), and 4.5-fold over those of healthy women (P < 0.001). Conclusions: Circulating levels of steroids were associated with increased risk of EC. Estrogens may represent novel biomarkers predictive of clinical characteristics, including evidence for an increased risk of relapse.

scholarly journals CANCER OF THE ORGANS OF THE REPRODUCTIVE SYSTEM IN WOMEN WITH TYPE 2 DIABETES. EFFECTS OF ANTIDIABETIC THERAPY

2020 ◽  
Vol 73 (5) ◽  
pp. 967-971
Author(s):  
Tamara S. Vatseba
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Postmenopausal Women ◽  
Reproductive System ◽  
Uterine Cancer ◽  
Antidiabetic Therapy ◽  
Increased Risk ◽  
Risk Of Cancer ◽  
The Impact

The aim: to investigate the prevalence of cancer of the reproductive system in women with type 2 diabetes, and to examine the impact of antidiabetic therapy on cancer risk of this localization. Materials and methods: The study included a retrospective analysis of medical records of women with T2D with first diagnosed cancer during 2012-2016. The bases for the study were specialized medical institutions in Ivano-Frankivsk region. The obtained results were processed using statistical programs “Microsoft Excel” and “Statistika-12”. Results: Breast, uterine, and ovarian cancer were detected in 202 postmenopausal women, 63.92% from the total number of cancer cases in women. An increased risk of breast [OR = 1.24; 95% CI (1.04 – 1.50) P = 0.019] and uterine cancer [OR = 1.32; 95% CI (1.02 – 1.69) P = 0.040] has been identified. Most often, before the detection of cancer, women received combination therapy with sulfonylurea and metformin (83 patients (57.64%)) with BMI 32.64 ± 3.69 kg/m2. The difference between risk of cancer on metformin monotherapy and on sulfonylurea monotherapy [OR = 2.17; 95% CI (0.88 – 5.36) P = 0.141] or on combination therapy [OR = 1.68; 95% CI (0.76 – 3.74) P = 0.276] was not found. Conclusions: Postmenopausal women have an increased risk of breast and uterine cancer and are recommended to be screened for these diseases

scholarly journals CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence

2017 ◽  
Vol 30 (7) ◽  
pp. 1032-1041 ◽  
Author(s):  
Katherine C Kurnit ◽  
Grace N Kim ◽  
Bryan M Fellman ◽  
Diana L Urbauer ◽  
Gordon B Mills ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Low Grade ◽  
Beta Catenin ◽  
Risk Of Recurrence ◽  
Increased Risk ◽  
Early Stage Endometrial Cancer

scholarly journals Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5439-5439
Author(s):  
Alexander Chan ◽  
Yanming Zhang ◽  
Sean M. Devlin ◽  
Natasha Lewis ◽  
Jeeyeon Baik ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Dendritic Cells ◽  
Stem Cell ◽  
Risk Category ◽  
Low Grade ◽  
Type I ◽  
Risk Of Death ◽  
Hla Dr ◽  
Increased Risk ◽  
Provision Of Services

Background Myelodysplastic syndrome (MDS) is a clonal, pre-leukemic stem cell disorder characterized by decreased blood counts due to ineffective hematopoiesis. Plasmacytoid dendritic cells (PDC) are stem cell derived, type I interferon producing dendritic cells, that are readily identifiable by flow cytometry (FC) using expression of CD123 and HLA-DR. PDCs have been shown to be decreased in acute myeloid leukemia (AML). Our study uses FC to evaluate PDC in MDS, their relationship to the Revised International Prognostic Scoring System (IPSS-R) for MDS, as well as their relationship to clinical outcomes. Methods We identified 197 patients with new MDS diagnoses and examined FC data of bone marrow aspirates (BMA) at first presentation to our institution for blast and PDC percentages. Patients who presented with an outside diagnosis of MDS greater than 1 year before presentation to our institution were excluded. MDS with excess blasts 1 and 2 (MDS-EB1/EB2) were designated as high grade, while MDS with isolated del5q (MDS-d5q), single lineage dysplasia (MDS-SLD), and multilineage dysplasia (MDS-MLD) were designated as low grade, with or without ring sideroblasts. 163 patients had sufficient data to calculate their IPSS-R risk categories. Sixteen patients with a history of solid tumor malignancies undergoing BMA for cytopenias were used as controls. The bone marrow of these control patients showed no evidence of morphologic dysplasia, they had normal karyotypes, and no pathogenic variants were detected on a 28 gene next generation sequencing based myeloid panel. We used CD34 and CD117 to quantify blasts, and CD123 and HLA-DR to quantify PDCs. Results The proportion of PDCs expressed as a percentage of total WBCs was significantly lower in higher risk MDS diagnoses (p <0.001) (Table 1A), as well as with worsening IPSS-R risk category (p <0.001) (Table 1B, Figure 1A). Sixteen percent of patients received disease modifying therapy (hypomethylating agents or lenalidomide) prior to presentation at our institution; PDC proportions in these patients were not significantly different from patients who presented untreated (p = 0.79). In the entire cohort, a lower proportion of PDC at the time of presentation was significantly associated with an increased risk of death (one-unit decrease in log PDC, HR 2.42, 95% CI 1.01-5.78, p = 0.046), but was not significantly associated with risk of progression to AML. Thirty-one patients progressed to AML, and these patients showed a significant decrease in the proportion of bone marrow PDCs at the time of progression to AML (p=0.002) (Table 1C, Figure 1B). Discussion This study demonstrates that PDC proportions decrease with MDS disease progression and are progressively lower as IPSS-R risk category increases. We also demonstrate that quantification of PDC in MDS can aid in predicting outcomes, although this may be due to a strong association with IPSS-R categories. FC is a useful and clinically feasible tool for quantitating PDCs in bone marrow aspirates, and this measurement is correlated with risk in MDS. Disclosures Arcila: Invivoscribe, Inc.: Consultancy, Honoraria. Roshal:Celgene: Other: Provision of Services; Auron Therapeutics: Equity Ownership, Other: Provision of services; Physicians' Education Resource: Other: Provision of services.

scholarly journals Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study

2016 ◽  
Vol 25 (9) ◽  
pp. 1348-1355 ◽  
Author(s):  
Cecilie L. Bager ◽  
Nicholas Willumsen ◽  
Stephanie N. Kehlet ◽  
Henrik B. Hansen ◽  
Anne-Christine Bay-Jensen ◽  
...  
Keyword(s):  
Risk Factor ◽  
Tumor Microenvironment ◽  
Postmenopausal Women ◽  
Increased Risk ◽  
Epidemiologic Risk ◽  
Risk Of Cancer ◽  
Epidemiologic Risk Factor

scholarly journals Sugar-Sweetened Beverage Intake and the Risk of Type I and Type II Endometrial Cancer among Postmenopausal Women

2013 ◽  
Vol 22 (12) ◽  
pp. 2384-2394 ◽  
Author(s):  
Maki Inoue-Choi ◽  
Kim Robien ◽  
Andrea Mariani ◽  
James R. Cerhan ◽  
Kristin E. Anderson
Keyword(s):  
Endometrial Cancer ◽  
Postmenopausal Women ◽  
Type I ◽  
Type Ii ◽  
Sugar Sweetened Beverage ◽  
Sweetened Beverage

scholarly journals Augmented serum levels of the IGF-I/IGF-binding protein-3 ratio in pre-menopausal patients with type I breast cysts

2003 ◽  
pp. 177-184 ◽  
Author(s):  
PJ Enriori ◽  
CR Fischer ◽  
AE Etkin ◽  
RS Calandra ◽  
IA Luthy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Binding Protein ◽  
Type I ◽  
Type Ii ◽  
Healthy Women ◽  
Increased Risk ◽  
Igf I ◽  
Igf Binding ◽  
Igf Binding Protein ◽  
Igfbp 3

OBJECTIVE: Gross cystic disease (GCD) is the most common benign breast pathology. Although breast cysts are not considered pre-malignant lesions, an increased risk of breast cancer has been reported for patients with type I cysts (Na(+)/K(+)<3). Furthermore, an augmented IGF-I/IGF-binding protein-3 (IGFBP-3) ratio has been described in breast cancer patients. The objective was to evaluate serum IGF-I and binding protein concentrations of type I and type II cyst patients as compared with healthy women. METHODS: Twenty-four patients with type I cysts, 17 with type II cysts and 25 healthy women were evaluated. Serum IGF-I, IGFBP-3 and IGFBP-1 concentrations were measured by IRMA. RESULTS: IGF-I concentrations were significantly higher in sera from patients with type I cysts than in patients with type II cysts. A highly significant decrease of IGFBP-3, the major IGFBP, was found in patients with type I cysts with respect to healthy women, whereas no significant difference was evident between the different cyst types. The IGF-I/IGFBP-3 ratio, an estimate of biologically active IGF-I, was very significantly higher in patients with type I cysts than in both type II patients and healthy women. IGFBP-1 levels were significantly lower in patients with type I than in controls and type II cysts. The IGF-I/IGFBP-1 ratio was significantly higher in patients with type I cysts than in type II bearers and healthy women. Estrogen levels correlated with IGF-I in patients and controls. CONCLUSIONS: The enhanced levels of IGF-I/IGFBP-3 found in patients with type I cysts could eventually be associated with the increased risk of breast cancer described for this group.

Fallowfield's Sexual Activity Questionnaire in women with without and at risk of cancer

2007 ◽  
Vol 13 (3) ◽  
pp. 103-109 ◽  
Author(s):  
Louise Atkins ◽  
Lesley J Fallowfield
Keyword(s):  
Ovarian Cancer ◽  
Sexual Activity ◽  
Menopausal Status ◽  
Sexually Active ◽  
Healthy Women ◽  
Increased Risk ◽  
Chemoprevention Trial ◽  
Risk Of Cancer ◽  
Risk Reducing ◽  
Activity Questionnaire

Objectives. To determine the effect of cancer, cancer risk, menopausal status and psychological factors on sexual activity as measured by Fallowfield's Sexual Activity Questionnaire (FSAQ). Study design and main outcome measures. Five groups of women completed the FSAQ: 1451 healthy women who were participating in an ovarian cancer screening trial; 488 healthy women at increased risk of breast cancer who were participating in a chemoprevention trial; 154 healthy women at increased risk of breast cancer who had been offered risk-reducing surgery; 117 women with advanced ovarian cancer; and a healthy non-study sample of 162 women. Results. There were significant between-group differences regarding age ( F=1373.79, P<0.01) and the proportion of women who were sexually active (χ2(4)=212.62, P<0.01) (more younger women reported being sexually active). The most commonly cited reason for sexual inactivity was the absence of a partner. In relation to their sexual activity, women with ovarian cancer reported less pleasure ( F=18.27, P<0.01), more discomfort ( F=21.33, P<0.01) and less frequency ( F=200.01, P<0.01) than the other groups. Premenopausal women reported more pleasure ( t=4.41, P<0.01), less discomfort ( t=11.79, P<0.01) and greater frequency of sexual activity ( t=8.58, P<0.01) than postmenopausal women. Psychological morbidity was associated with decreased pleasure in sexual activity among the women with an elevated risk of cancer – that is, those participating in the chemoprevention trial ( t=4.20, P<0.01) and those offered risk-reducing surgery ( t=3.32, P<0.01). Conclusions: The FSAQ is a useful tool for measuring sexual activity in women with cancer and women at a normal or increased risk of developing cancer. Age, cancer, psychological distress and menopausal status affect sexual activity in these groups of women and should be considered in future investigations.

TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies

2003 ◽  
Vol 21 (17) ◽  
pp. 3236-3243 ◽  
Author(s):  
Virginia G. Kaklamani ◽  
Nanjiang Hou ◽  
Yiansong Bian ◽  
Jennifer Reich ◽  
Kenneth Offit ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
The United States ◽  
Case Control ◽  
Type I ◽  
Susceptibility Allele ◽  
Case Control Studies ◽  
Tumor Susceptibility ◽  
Increased Risk ◽  
Risk Of Cancer

Purpose: TGFBR1*6A is a hypomorphic polymorphic allele of the type I transforming growth factor beta receptor (TGFBR1). TGFBR1*6A is a candidate tumor susceptibility allele that has been associated with an increased incidence of various types of cancer. This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer. Patients and Methods: All published case-control studies assessing the germline frequency of TGFBR1*6A were included. Studies assessing TGFBR1*6A in tumors were excluded. The results of seven studies comprising 2,438 cases and 1,846 controls were pooled and analyzed. Results: Overall, TGFBR1*6A carriers have a 26% increased risk of cancer (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.07 to 1.49). Cancer risk for TGFBR1*6A homozygotes (OR, 2.53; 95% CI, 1.39 to 4.61) is twice that of TGFBR1*6A heterozygotes (OR, 1.26; 95% CI, 1.04 to 1.51). Analysis of various types of tumors shows that TGFBR1*6A carriers are at increased risk of developing breast cancer (OR, 1.48; 95% CI, 1.11 to 1.96), hematological malignancies (OR, 1.70; 95% CI, 1.13 to 2.54), and ovarian cancer (OR, 1.53; 95% CI, 1.07 to 2.17). Carriers of TGFBR1*6A who are from the United States are at increased risk of colorectal cancer (OR, 1.38; 95% CI, 1.02 to 1.86). However, Southern European TGFBR1*6A carriers have no increased colorectal cancer risk. There is no association between TGFBR1*6A and bladder cancer. Conclusion: TGFBR1*6A is emerging as a highfrequency, low-penetrance tumor susceptibility allele that predisposes to the development of breast, ovarian, and colorectal cancer, as well as hematologic malignancies.

Sign in / Sign up

Export Citation Format

Share Document